EXELIXIS, INC.

EXEL

EXELIXIS, INC.

EXEL

Insider Sentiment (TTM):

Last Purchase:2025-11-25Last Sale:2026-06-01Shares Purchased (TTM):27,532Shares Sold (TTM):816,567

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:242,898,799Shares Outstanding:258,329,000Institutional Ownership Pct.:94.03%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	281	226	482	376	164	184	217	258	198	260	263	397
Short Term Investments	-	-	-	-	-	-	-	-	804	704	732	707
Marketable Securities Current	558	551	577	612	627	848	894	931	-	-	732	-
Receivables Net Current	322	329	287	310	292	282	265	270	397	241	237	248
Inventory Net	29	27	22	27	23	25	22	21	21	21	17	25
Prepaid Expense And Other Assets Current	60	76	76	77	74	59	68	70	58	67	68	67
Assets Current	1,251	1,209	1,443	1,402	1,181	1,397	1,468	1,550	1,477	1,292	1,318	1,443
Long Term Investments	-	-	-	-	-	-	-	-	432	630	729	812
Marketable Securities Noncurrent	545	649	604	578	595	619	637	523	-	-	729	-
Property Plant And Equipment Net	93	96	99	105	110	115	119	124	130	127	129	121
Deferred Income Tax Assets Net	294	294	293	419	419	419	420	359	362	362	361	231
Goodwill	64	64	64	64	64	64	64	64	64	64	64	64
Assets	2,494	2,594	2,844	2,824	2,678	2,837	2,948	2,960	2,773	2,804	2,942	2,977
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	39	24	30	25	26	43	38	59	29	26	34	26
Accrued Employee Benefits Current	69	88	102	104	72	90	110	91	72	73	93	81
Customer Refund Liability Current	67	66	60	58	57	58	62	62	58	76	60	54
Other Liabilities Current	103	100	125	105	101	126	95	96	103	104	108	124
Liabilities Current	362	371	406	374	336	399	404	394	346	373	394	377
Operating Lease Liability Noncurrent	166	170	173	176	180	187	191	194	198	201	190	191
Other Liabilities Noncurrent	123	117	104	113	129	120	109	96	110	101	94	62
Liabilities	650	658	683	663	645	706	703	685	653	676	678	629
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	2,108	2,152	2,234	2,263	2,251	2,292	2,344	2,361	2,325	2,392	2,441	2,487
Accumulated Other Comprehensive Income Loss Net Of…	-2	-0	3	4	1	2	-1	4	-5	-5	-4	-14
Retained Earnings Accumulated Deficit	-263	-216	-77	-106	-220	-163	-99	-90	-200	-259	-173	-126
Stockholders Equity	1,844	1,936	2,161	2,161	2,034	2,131	2,244	2,275	2,120	2,128	2,264	2,348
Liabilities And Stockholders Equity	2,494	2,594	2,844	2,824	2,678	2,837	2,948	2,960	2,773	2,804	2,942	2,977
Preferred Stock Number Of…
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Number Of Sh…
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	400	400	400
Common Stock Shares Issued	249	254	262	268	270	275	282	286	285	295	303	311
Shares Outstanding	249	254	262	268	270	275	282	286	285	295	303	311

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	13.64%	23.30%	24.65%	-	-	-	-	-	-	-	-	-
2025	16.45%	24.90%	0.84%	-12.98%	-9.66%	-11.58%	16.54%	22.01%	16.81%	-3.33%	2.09%	1.63%
2024	-12.32%	-5.37%	-3.67%	11.00%	10.70%	18.85%	23.95%	15.87%	26.00%	17.59%	5.36%	20.69%
2023	-	-	-	-	-	-	3.14%	13.89%	6.95%	1.88%	8.70%	8.57%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.46	3.26	3.56	3.75	3.51	3.50	3.63	3.93	4.27	3.46	3.34	3.83
Quick Ratio	3.21	2.98	3.32	3.47	3.22	3.29	3.41	3.70	4.05	3.23	3.13	3.59
Working Capital	888.90M	837.66M	1.04B	1.03B	844.65M	997.40M	1.06B	1.16B	1.13B	919.42M	923.68M	1.07B
Leverage & Debt
Debt to Equity	0.35	0.34	0.32	0.31	0.32	0.33	0.31	0.30	0.31	0.32	0.30	0.27
Debt Ratio	0.26	0.25	0.24	0.23	0.24	0.25	0.24	0.23	0.24	0.24	0.23	0.21
Efficiency & Turnover
Asset Turnover TTM	0.94	0.87	0.80	0.79	0.82	0.82	0.74	0.70	0.68	0.62	0.61	0.60
Days Sales Outstanding TTM	46.04	46.91	43.45	46.21	56.38	41.46	42.32	45.40	57.03	46.89	45.09	47.63
Receivables Turnover TTM	7.93	7.78	8.40	7.90	6.47	8.80	8.63	8.04	6.40	7.78	8.09	7.66
Per Share Metrics
Diluted EPS TTM	3.31	3.12	2.78	2.43	2.12	2.23	1.76	1.60	1.19	0.67	0.65	0.29
Free Cash Flow Per Share TTM	4.67	3.55	3.23	2.91	2.77	2.94	2.32	1.51	0.96	0.93	0.92	1.14
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	96.48%	96.44%	96.39%	96.63%	96.59%	96.78%	96.49%	96.25%	96.06%	95.70%	96.04%	96.24%
Operating Profit Margin TTM	39.88%	39.43%	37.59%	34.97%	31.38%	33.15%	27.88%	25.13%	18.35%	9.29%	9.34%	2.31%
Net Profit Margin TTM	35.33%	35.08%	33.73%	29.63%	27.01%	27.99%	24.04%	22.43%	17.38%	11.10%	11.35%	5.19%
Growth Metrics
Net Revenue Growth (1Y)	9.23%	3.33%	6.98%	9.93%	10.73%	24.49%	18.49%	17.31%	17.48%	10.98%	13.60%	8.31%
Net Income Growth (1Y)	42.89%	29.50%	50.13%	45.18%	72.09%	213.85%	150.89%	407.12%	113.09%	33.38%	13.98%	-70.07%
EPS Growth (1Y)	55.30%	39.76%	60.34%	54.49%	82.59%	238.56%	175.22%	460.16%	138.87%	43.87%	15.19%	-69.44%
Valuation Metrics
P/E TTM	15.86	13.29	15.21	16.35	19.95	15.99	18.53	15.87	18.57	34.81	36.74	74.87
P/B TTM	7.40	5.72	5.51	5.13	5.91	4.83	4.30	3.26	3.07	3.35	3.37	2.94
P/S TTM	5.60	4.66	5.13	4.84	5.39	4.48	4.45	3.56	3.23	3.86	4.17	3.88
Market Cap	13.65B	11.08B	11.90B	11.09B	12.02B	10.29B	9.66B	7.41B	6.50B	7.14B	7.63B	6.89B
Enterprise Value	13.37B	10.85B	11.42B	10.71B	11.85B	10.11B	9.44B	7.15B	6.30B	6.88B	7.37B	6.50B
Calculated Values
Free Cash Flow TTM	1.17B	917.69M	875.84M	779.77M	754.07M	820.89M	671.54M	432.69M	277.54M	279.60M	292.86M	359.40M
Net Debt	-281.45M	-226.15M	-482.49M	-376.30M	-164.43M	-183.75M	-217.37M	-258.35M	-198.46M	-259.56M	-262.99M	-396.86M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-01Sale

Owner: Eckhardt, Sue Gail

Title: -

Shares: 9,812

Price/Share: $50.14

Value: $491,973.68

Shares Owned: 16,079

Relationship: Director

Ownership: Direct

2026-06-01Sale

Owner: Wyszomierski, Jack L

Title: -

Shares: 3,925

Price/Share: $50.55

Value: $198,408.75

Shares Owned: 284,384

Relationship: Director

Ownership: Direct

2026-05-26Sale

Owner: Aftab, Dana

Title: EVP, Research and Development

Shares: 43,451

Price/Share: $50.35

Value: $2,187,757.85

Shares Owned: 594,741

Relationship: Officer

Ownership: Direct

2026-05-20Sale

Owner: Haley, Patrick J.

Title: EVP, Commercial

Shares: 32,110

Price/Share: $49.81

Value: $1,599,399.10

Shares Owned: 357,638

Relationship: Officer

Ownership: Direct

2026-05-18Sale

Owner: Senner, Christopher J.

Title: EVP and CFO

Shares: 34,901

Price/Share: $50.00

Value: $1,745,050.00

Shares Owned: 952,317

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-01	Eckhardt, Sue Gail	Director	-	Direct	Sale	9,812	50.14	$491,973.68	16,079	4
2026-06-01	Wyszomierski, Jack L	Director	-	Direct	Sale	3,925	50.55	$198,408.75	284,384	4
2026-05-26	Aftab, Dana	Officer	EVP, Research and Development	Direct	Sale	43,451	50.35	$2,187,757.85	594,741	4
2026-05-20	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	32,110	49.81	$1,599,399.10	357,638	4
2026-05-18	Senner, Christopher J.	Officer	EVP and CFO	Direct	Sale	34,901	50.00	$1,745,050.00	952,317	4
2026-05-18	Hefti, Brenda	Officer	SVP and General Counsel	Direct	Sale	6,625	50.21	$332,641.25	106,762	4
2026-05-07	Beckerle, Mary C	Director	-	Direct	Sale	7,712	48.45	$373,646.40	17,524	4
2026-05-07	Poste, George	Director	-	Direct	Sale	60,000	45.71	$2,742,600.00	118,832	4
2026-05-07	Freire, Maria C	Director	-	Direct	Sale	20,634	46.00	$949,164.00	100,819	4
2026-02-24	Aftab, Dana	Officer	EVP, Research and Development	Direct	Sale	47,918	44.50	$2,132,351.00	616,106	4
2026-02-19	Aftab, Dana	Officer	EVP, Research and Development	Direct	Sale	29,873	44.35	$1,324,867.55	664,024	4
2026-02-18	Hefti, Brenda	Officer	SVP and General Counsel	Direct	Sale	18,669	44.01	$821,622.69	96,512	4
2026-02-18	Smith, Julie	Director	-	Direct	Sale	64,117	44.40	$2,846,794.80	20,590	4
2026-02-18	Wyszomierski, Jack L	Director	-	Direct	Sale	99,574	44.01	$4,382,251.74	279,942	4
2026-02-17	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	67,814	43.67	$2,961,437.38	381,908	4
2026-02-13	Senner, Christopher J.	Officer	EVP and CFO	Direct	Sale	34,278	43.00	$1,473,954.00	1,042,579	4
2026-02-13	Oliver, Bob	Director	-	Direct	Sale	30,250	43.76	$1,323,740.00	21,120	4
2026-02-13	Eckhardt, Sue Gail	Director	-	Direct	Sale	3,856	43.79	$168,854.24	17,524	4
2025-11-25	Caligan, Partners Lp, Joh…	Director	-	Indirect	Purchase	27,532	43.12	$1,187,179.84	1,553,262	4
2025-11-21	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	28,043	42.58	$1,194,070.94	374,029	4
2025-11-12	Papadopoulos, Stelios	Director	-	Direct	Sale	100,000	43.55	$4,355,000.00	1,189,228	4
2025-11-11	Beckerle, Mary C	Director	-	Direct	Sale	24,622	41.96	$1,033,139.12	21,380	4
2025-11-11	Aftab, Dana	Officer	EVP, Research and Development	Direct	Sale	48,383	42.50	$2,056,277.50	664,778	4
2025-06-03	Wyszomierski, Jack L	Director	-	Direct	Sale	7,535	43.09	$324,683.15	358,882	4
2025-06-02	Eckhardt, Sue Gail	Director	-	Direct	Sale	18,838	43.20	$813,801.60	21,380	4
2025-05-21	Heyman, Tomas J.	Director	-	Direct	Sale	4,544	44.29	$201,253.76	32,470	4
2025-05-20	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	34,387	44.06	$1,515,091.22	412,072	4
2025-05-16	Peterson, Amy C.	Officer	EVP Prod Dev & Med Aff & CMO	Direct	Sale	72,776	45.47	$3,309,124.72	465,393	4
2025-05-16	Senner, Christopher J.	Officer	EVP and CFO	Direct	Sale	100,000	46.00	$4,600,000.00	967,842	4
2025-05-16	Poste, George	Director	-	Direct	Sale	20,634	45.99	$948,957.66	169,020	4
2025-05-15	Papadopoulos, Stelios	Director	-	Direct	Sale	36,508	44.35	$1,619,129.80	1,279,416	4
2025-05-15	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	126,383	47.50	$6,003,192.50	446,459	4
2025-05-15	Hessekiel, Jeffrey	Officer	EVP & General Counsel	Direct	Sale	25,000	46.18	$1,154,500.00	693,396	4
2025-05-01	Aftab, Dana	Officer	CSO/EVP Disc & Trans Research	Direct	Sale	1,508	39.00	$58,812.00	693,181	4
2025-03-03	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	10,000	38.80	$388,000.00	341,028	4
2025-02-28	Wyszomierski, Jack L	Director	-	Direct	Sale	8,768	37.80	$331,430.40	356,605	4
2025-02-28	Smith, Julie	Director	-	Direct	Sale	19,294	37.62	$725,840.28	10,778	4
2025-02-25	Oliver, Bob	Director	-	Direct	Sale	18,647	37.25	$694,600.75	33,514	4
2025-02-24	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	52,636	36.98	$1,946,479.28	303,310	4
2025-02-24	Senner, Christopher J.	Officer	EVP and CFO	Direct	Sale	29,314	36.14	$1,059,407.96	779,607	4
2025-02-24	Aftab, Dana	Officer	CSO/EVP Disc & Trans Research	Direct	Sale	26,987	36.75	$991,772.25	511,908	4
2025-02-14	Eckhardt, Sue Gail	Director	-	Direct	Sale	11,568	35.02	$405,111.36	30,406	4
2025-02-14	Freire, Maria C	Director	-	Direct	Sale	44,114	34.94	$1,541,343.16	91,007	4
2025-02-14	Poste, George	Director	-	Direct	Sale	15,874	34.74	$551,462.76	169,020	4
2025-02-14	Beckerle, Mary C	Director	-	Direct	Sale	12,210	34.88	$425,884.80	30,406	4
2024-11-29	Hessekiel, Jeffrey	Officer	EVP & General Counsel	Direct	Sale	60,000	36.67	$2,200,200.00	486,059	4
2024-11-22	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	10,000	35.27	$352,700.00	278,665	4
2024-11-18	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	41,588	34.36	$1,428,963.68	288,665	4
2024-11-05	Aftab, Dana	Officer	CSO/EVP Disc & Trans Research	Direct	Sale	96,986	35.00	$3,394,510.00	498,945	4
2024-11-01	Poste, George	Director	-	Direct	Sale	30,000	34.00	$1,020,000.00	169,020	4
2024-11-01	Hessekiel, Jeffrey	Officer	EVP & General Counsel	Direct	Sale	50,000	34.13	$1,706,500.00	530,325	4
2024-10-30	Aftab, Dana	Officer	CSO/EVP Disc & Trans Research	Direct	Sale	1,162	31.40	$36,486.80	498,945	4
2024-10-28	Hessekiel, Jeffrey	Officer	EVP & General Counsel	Direct	Sale	25,000	28.39	$709,750.00	580,325	4
2024-09-23	Hessekiel, Jeffrey	Officer	EVP & General Counsel	Direct	Sale	25,000	26.38	$659,500.00	605,325	4
2024-08-26	Hessekiel, Jeffrey	Officer	EVP, General Counsel & Sec	Direct	Sale	20,000	25.79	$515,800.00	630,325	4
2024-08-14	Freire, Maria C	Director	-	Direct	Sale	8,250	26.56	$219,120.00	91,007	4
2024-08-12	Aftab, Dana	Officer	CSO/EVP Disc & Trans Research	Direct	Sale	20,883	27.06	$565,093.98	500,107	4
2024-08-09	Senner, Christopher J.	Officer	EVP and CFO	Direct	Sale	125,000	27.19	$3,398,750.00	721,680	4
2024-08-08	Poste, George	Director	-	Direct	Sale	33,725	26.89	$906,865.25	199,020	4
2024-08-07	Aftab, Dana	Officer	CSO/EVP Disc & Trans Research	Direct	Sale	95,000	25.00	$2,375,000.00	520,990	4
2024-08-07	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	14,000	25.50	$357,000.00	341,036	4
2024-08-07	Hessekiel, Jeffrey	Officer	EVP, General Counsel & Sec	Direct	Sale	80,000	25.97	$2,077,600.00	630,325	4
2024-06-04	Wyszomierski, Jack L	Director	-	Direct	Sale	8,287	22.00	$182,314.00	349,499	4
2024-05-30	Johnson, David Edward, Ca…	Director,Other	-	Indirect	Purchase	225,000	20.76	$4,671,000.00	1,525,730	4
2024-05-21	Smith, Julie	Director	-	Direct	Sale	27,280	21.12	$576,153.60	5,445	4
2024-05-21	Poste, George	Director	-	Direct	Sale	11,686	20.96	$244,938.56	213,907	4
2024-05-20	Papadopoulos, Stelios	Director	-	Direct	Sale	11,437	21.00	$240,177.00	1,260,578	4
2024-05-13	Wyszomierski, Jack L	Director	-	Direct	Sale	10,923	21.37	$233,424.51	338,948	4
2024-03-21	Garber, Alan M	Director	-	Direct	Sale	19,205	24.01	$461,112.05	35,703	4
2024-02-23	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	47,020	21.45	$1,008,579.00	384,866	4
2024-02-21	Caligan, Partners Lp, Joh…	Director	-	Indirect	Purchase	190,000	20.70	$3,933,000.00	1,100,730	4
2023-12-14	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	50,000	23.35	$1,167,500.00	307,687	4
2023-12-13	Hessekiel, Jeffrey	Officer	EVP, General Counsel & Sec	Direct	Sale	25,000	23.01	$575,250.00	533,345	4
2023-12-04	Hessekiel, Jeffrey	Officer	EVP, General Counsel & Sec	Direct	Sale	25,000	22.06	$551,500.00	558,345	4
2023-11-27	Caligan, Partners Lp, Joh…	Director	-	Indirect	Sale	120,409	21.61	$2,602,038.49	790,321	4
2023-11-27	Caligan, Partners Lp, Joh…	Director	-	Indirect	Purchase	120,409	21.61	$2,602,038.49	910,730	4
2023-08-30	Aftab, Dana	Officer	CSO/EVP Disc & Trans Research	Direct	Sale	4,600	22.47	$103,362.00	399,943	4
2023-08-04	Senner, Christopher J.	Officer	EVP and CFO	Direct	Sale	60,000	20.68	$1,240,800.00	571,631	4
2023-08-03	Haley, Patrick J.	Officer	EVP, Commercial	Direct	Sale	30,553	20.67	$631,530.51	285,467	4
2023-08-01	Hessekiel, Jeffrey	Officer	EVP, General Counsel & Sec	Direct	Sale	55,710	19.63	$1,093,587.30	571,976	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

94.03%

Inst. Shares: 242,898,799

Shares Outstanding: 258,329,000

2025-12-31

90.44%

Inst. Shares: 245,614,774

Shares Outstanding: 271,567,000

2025-09-30

88.24%

Inst. Shares: 236,845,305

Shares Outstanding: 268,421,000

2025-06-30

87.82%

Inst. Shares: 239,369,780

Shares Outstanding: 272,583,000

2025-03-31

83.44%

Inst. Shares: 232,645,378

Shares Outstanding: 278,804,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	242,898,799	258,329,000	94.03%
2025-12-31	245,614,774	271,567,000	90.44%
2025-09-30	236,845,305	268,421,000	88.24%
2025-06-30	239,369,780	272,583,000	87.82%
2025-03-31	232,645,378	278,804,000	83.44%
2024-12-31	232,831,389	290,030,000	80.28%
2024-09-30	226,438,176	285,622,000	79.28%
2024-06-30	227,475,117	289,216,000	78.65%
2024-03-31	219,313,953	300,757,000	72.92%
2023-12-31	229,693,381	318,151,000	72.20%
2023-09-30	229,949,671	315,496,000	72.89%
2023-06-30	238,427,539	324,205,000	73.54%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

EXELIXIS, INC. (EXEL) — SEC Financial Statements & Analysis

EXELIXIS, INC. (EXEL) is a biological products, (no diagnostic substances) company, incorporated in DE. EXELIXIS, INC. trades on Nasdaq as: EXEL. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), EXELIXIS, INC. reported a 9.23% year-over-year revenue growth, a Gross Profit Margin of 96.48% (TTM), a Debt-to-Equity ratio of 0.35x, a Price-to-Sales (P/S) ratio of 5.60x (TTM), a Price-to-Book (P/B) ratio of 7.40x (TTM), at a market cap of $13.65B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 9.23%
Gross Profit Margin TTM: 96.48%
Debt To Equity: 0.35x
P/S TTM: 5.60x
P/B TTM: 7.40x
Market Cap: $13.65B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is EXELIXIS, INC. in?

EXELIXIS, INC. (EXEL) operates in the Biological Products, (No Diagnostic Substances) industry.

What is EXEL's market cap?

EXELIXIS, INC. (EXEL) has a market capitalization of $13.65B as of 2026-06-30.

What is EXEL's P/E ratio?

EXELIXIS, INC. (EXEL)'s trailing twelve month P/E ratio is 15.86x as of 2026-06-30.

What exchange does EXEL trade on?

EXELIXIS, INC. (EXEL) trades on the Nasdaq.

Where is EXELIXIS, INC. incorporated?

EXELIXIS, INC. is incorporated in DE.

EXELIXIS, INC.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

EXELIXIS, INC. (EXEL) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.
Main Street's price.

EXELIXIS, INC. (EXEL) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.